Table 2.

Kaplan–Meier estimates of the cumulative incidences of strict and clinical FRNS

3-Month Group (n=62)6-Month Group (n=64)Difference (%; 95% CI)Log Rank Test
Strict FRNS (%)
 6 months14.5±4.53.1±2.2−11.40 (−21.20, −1.60)
 1 year38.7±6.239.1±6.10.40 (−16.60, 17.40)
 2 years45.2±6.345.6±6.20.40 (−16.90, 17.70)
 3 years45.2±6.349.3±6.44.10 (−13.50, 21.70)
 4 years45.2±6.352.5±6.77.30 (−10.70, 25.30)
 5 years45.2±6.352.5±6.77.30 (−10.70, 25.30)P=0.91
Clinical FRNS (%)
 6 months17.7±4.910.9±3.9−6.80 (−19.10, 5.50)
 1 year41.9±6.346.9±6.25.00 (−9.10, 19.10)
 2 years50.1±6.453.3±6.33.20 (−14.40, 20.80)
 3 years50.1±6.459.4±6.49.30 (−8.40, 27.00)
 4 years50.1±6.459.4±6.412.20 (−5.70, 30.10)
 5 years50.1±6.462.3±6.512.20 (−5.70, 30.10)P=0.76
  • Data are expressed as percentages ± SEMs at 6 months and yearly afterward. Between-group differences are expressed as percentages with 95% CIs. Log rank tests were performed on all available data at the end of follow-up. Clinical FRNS, FRNS according to the definition of strict FRNS or other indications for additional treatment measures (e.g., prednisolone maintenance therapy, ciclosporin, etc.); strict FRNS, FRNS based on more than or equal to two relapses within 6 months after initial treatment or four relapses within any 12 months.